ArriVent is a US-based biopharma company dedicated to accelerating the global development of innovative biopharmaceutical products.
Location: United States, Pennsylvania, Newtown Township
Total raised: $415M
Investors 5
| Date | Name | Website |
| - | Octagon Ca... | octagoninv... |
| 14.04.2023 | Sofinnova ... | sofinnova.... |
| - | OrbiMed | orbimed.co... |
| 05.06.2023 | HBM Partne... | hbmpartner... |
| - | Catalio Ca... | cataliocap... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 28.03.2023 | Series B | $155M | - |
| 28.12.2022 | Series B | $110M | - |
| 03.07.2021 | - | $150M | Octagon Ca... |
Mentions in press and media 12
| Date | Title | Description |
| 16.08.2024 | Alphamab Oncology Reports 2024 Interim Results and Business Highlights | SUZHOU, China, Aug. 16, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) reported interim financial results for the six months ended June 30, 2024 and highlighted recent business progress. Financial Summary For the six months en... |
| 06.06.2024 | Alphamab Oncology Collaborated with ArriVent in relation to the Research, Development and Commercialization of ADC Products | SUZHOU, China, June 6, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Alphamab"), a wholly-owned subsidiary of the Company, entered into a research and c... |
| 26.01.2024 | ArriVent’s Nasdaq Debut Nabs $175M as Signs Indicate an Opening IPO Window | Cancer drug developer ArriVent BioPharma has a lead program with the potential to treat lung cancers characterized by certain rare mutations. A pivotal study is underway and the biotech now has $175 million in IPO cash to continue the small... |
| 28.03.2023 | Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments announces the return of Dr Andreas Wicki; new investment of USD 12 million in ArriVent Biopharma | HBM Healthcare Investments refers to its media release dated 30 January 2023. Dr Andreas Wicki has recovered from his health matters and will fully resume his duties as Chief Executive Officer of HBM Healthcare Investments and with the inve... |
| 27.03.2023 | ArriVent Biopharma Closes $155M in Series B Financing | ArriVent Biopharma, a Newtown Square, PA-based company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, raised $155M in Series B funding. The round was led by Sofinnova Investments and General C... |
| 27.03.2023 | ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing | - |
| 27.03.2023 | ArriVent Biopharma Closes $155M Series B Financing | NEWTOWN SQUARE, PA, ArriVent Biopharma announces $155M oversubscribed Series B financing led by Sofinnova Investments and General Catalyst. >> Click here for more funding data on ArriVent Biopharma >> To export ArriVent Biop... |
| 27.03.2023 | ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing | - |
| 05.01.2023 | Monday Moves: 3 Philly biotech companies are starting 2023 with fresh funding | Money Moves is a column where we chart the funding raises of tech companies across the region. Have a tip? Email us at philly@technical.ly. ArriVent Biopharma raises $110 million Newtown Square-based biopharmaceutical company ArriVent Bioph... |
| 30.06.2021 | ArriVent raises $150M to bring Chinese drugs to Western markets | ArriVent Biopharma has raised up to $150 million to in-license assets from China and other emerging biotech hubs and develop them for use in other markets. The biotech has already picked up ex-China rights to an EGFR TKI that it plans to st... |
Show more